



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer / Chen, Jingjing; Guccini, Ilaria; Mitri, Diletta Di; Brina, Daniela; Revandkar, Ajinkya; Sarti, Manuela; Pasquini, Emiliano; Alajati, Abdullah; Pinton, Sandra; Losa, Marco; Civenni, Gianluca; Catapano, Carlo V.; Sgrignani, Jacopo; Cavalli, Andrea; D'Antuono, Rocco; Asara, John M.; Morandi, Andrea; Chiarugi, Paola;

Availability:

The webpage <https://hdl.handle.net/2158/1118953> of the repository was last updated on 2018-03-14T16:21:09Z

Published version:

DOI: 10.1038/s41588-017-0026-3

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

Published in final edited form as:

Nat Genet. 2018 February ; 50(2): 219–228. doi:10.1038/s41588-017-0026-3.

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

Jingjing Chen^{1,3}, Ilaria Guccini¹, Diletta Di Mitri¹, Daniela Brina¹, Ajinkya Revandkar^{1,3}, Manuela Sarti¹, Emiliano Pasquini¹, Abdullah Alajati¹, Sandra Pinton¹, Marco Losa¹, Gianluca Civenni¹, Carlo V. Catapano¹, Jacopo Sgrignani⁴, Andrea Cavalli⁴, Rocco D'Antuono⁵, John M. Asara⁶, Andrea Morandi⁷, Paola Chiarugi⁷, Sara Crotti⁸, Marco Agostini^{8,9}, Monica Montopoli¹⁰, Ionica Masgras¹¹, Andrea Rasola¹¹, Ramon Garcia-Escudero^{12,13,14}, Nicolas Delaleu¹⁵, Andrea Rinaldi¹, Francesco Bertoni¹, Johann de Bono¹⁶, Arkaitz Carracedo^{14,17,18,19}, and Andrea Alimonti^{1,2,3}

¹Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland ²Department of Medicine, Venetian Institute of Molecular Medicine, University of Padova, Padova, Italy ³Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland ⁴Computational Structural Biology, Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland ⁵Imaging Facility, Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland ⁶Division of Signal Transduction, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA ⁷Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy ⁸Nano-inspired Biomedicine Lab, Institute of Paediatric Research - Città della Speranza, Padova, Italy ⁹Surgical Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy ¹⁰Department Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy ¹¹CNR

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence and requests for materials should be addressed to A.A. (andrea.alimonti@ior.ios.ch).

URLs

Gene Expression Omnibus, <https://www.ncbi.nlm.nih.gov/geo/>; MetaboAnalyst, <http://www.metaboanalyst.ca/>; UCSC Genome Browser on Human, https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr8%3A124998506-125022283&hgslid=641911343_mdAzqHRm9nypyskAklqb2aiYGn1X

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

J.C. and A.A. originally conceived the concept, designed the experiments, interpreted the data and wrote the paper. J.C., I.G., D.B., A.R. and A. Alajati performed experiments and analyzed the data. J.C. crossed and generated transgenic mouse model. G.C., E.P. and J.C. made experiments on xenograft mouse model. A. Alajati., S.P., M.L., M.S. and J.D.B. performed immune-histochemical experiments and analysis. R.D. and J.C. established and carried out fluorescence microscopy. J.M.A. and J.C. conducted metabolomics and lipidomics analysis on mouse prostate tumours. S. C., M. A., M.M. and J.C. performed cholesterol measurements in prostate cancer cell lines. A.M. and P.C. performed carbon-14 tracing experiments and interpreted data. I.M. and A.R. carried out mitochondrial OCR measurements. A.R., N.D. and F.B. performed gene expression profile on mouse tumours and GSEA analysis of metabolic pathways on mouse tumours. R.G.E. provided bioinformatics analysis on PDHA1 and PDP1 amplification and overexpression in human prostate cancer datasets. A.C. provided support on metabolic analysis, interpretation of results and discussion.

Competing interests

The authors declare no competing financial interests.

Institute of Neuroscience and Department of Biomedical Sciences, University of Padova, Padova, Italy ¹²Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain ¹³Biomedical Research Institute I+12, University Hospital 12 de Octubre, Madrid, Spain ¹⁴Centro de Investigación Biomédica en Red de Cáncer, Spain ¹⁵Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway ¹⁶Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, United Kingdom ¹⁷CIC bioGUNE, Bizkaia Technology Park, Bizkaia, Spain ¹⁸Ikerbasque, Basque Foundation for Science, Bilbao, Spain ¹⁹Biochemistry and Molecular Biology Department, University of the Basque Country, Bilbao, Spain

Abstract

The mechanisms by which mitochondrial metabolism supports cancer anabolism are still unclear. Here, we unexpectedly find that genetic and pharmacological inactivation of Pyruvate Dehydrogenase A1 (PDHA1), a subunit of pyruvate dehydrogenase complex (PDC) inhibits prostate cancer development in different mouse and human xenograft tumour models by affecting lipid biosynthesis. Mechanistically, we show that in prostate cancer, PDC localizes in both mitochondria and nucleus. While nuclear PDC controls the expression of Sterol regulatory element-binding transcription factor (SREBF) target genes by mediating histone acetylation, mitochondrial PDC provides cytosolic citrate for lipid synthesis in a coordinated effort to sustain anabolism. In line with these evidence, we find that PDHA1 and the PDC activator, Pyruvate dehydrogenase phosphatase 1 (PDP1), are frequently amplified and overexpressed at both gene and protein level in prostate tumours. Taken together, these findings demonstrate that both mitochondrial and nuclear PDC sustain prostate tumorigenesis by controlling lipid biosynthesis thereby pointing at this complex as a novel target for cancer therapy.

Mitochondrial metabolism is a source of energy and metabolic intermediates that serve various purposes, from redox homeostasis to anabolism or epigenetics¹. There is an emerging association between increased mitochondrial metabolism and cancer pathogenesis and progression, but the molecular means underlying this biological process are still unknown^{1–10}. The pyruvate dehydrogenase complex (PDC) is a gatekeeper multi-protein complex that catalyzes the conversion of pyruvate to acetyl coenzyme A (acetyl coA) thereby regulating the mitochondrial activity. This complex includes a major component, PDHA1, that can be dephosphorylated by the Pyruvate dehydrogenase phosphatase (PDPs) Pdp1 and Pdp2 and phosphorylated by the pyruvate dehydrogenase kinases (Pdk)^{11–13}. While dephosphorylation of PDHA1 activates the PDC, phosphorylation blocks its activity. In turn, we postulated that by impairing the function of PDHA1 and the PDC we would hamper mitochondrial metabolism and ascertain its consequences in prostate cancer biology.

Results

***Pdha1* knockout induces tumour suppression in mice and human prostate tumours**

We thus inactivated *Pdha1*, in *Pten*-null prostate conditional (*Pten*^{PC-/-}) mice that develop high-grade intra-epithelial prostate tumours at an early age and invasive prostate cancer at late age 14–16. The presence of Cre recombinase, the recombination of the *Pten* exon 4 and 5 and *Pdha1* exon 8, in *Pten*^{PC-/-}; *Pdha1*^{PC-/Y} prostates were verified by genotyping 14, 17, 18 (Supplementary Fig. 1a). Notably, *Pten*^{PC-/-} mice develop tumours characterized by increased mRNA and/or protein levels of both *Pdha1*, *Dlat*, *Dld* and *Pdp1*, but not *Pdp2* or *Pdks*, and an increased PDC activity as compared to normal prostates (Fig. 1a, b, Supplementary Fig. 1b and uncropped blots in Supplementary Fig. 12). Inactivation of *Pdha1* in *Pten*^{PC-/-} tumours abrogated PDC activity and induced a strong growth inhibition in all the prostate glands of mice of different ages (Fig. 1c). This was associated with a strong reduction in cell proliferation as shown by the decreased Ki-67 staining and number of glands affected by invasive prostate cancer (Fig. 1d-f and Supplementary Fig. 1c). The strong arrest in proliferation in *Pten*^{PC-/-}; *Pdha1*^{PC-/Y} tumours and *Pten*^{-/-}; *Pdha1*^{-/Y} MEFs occurred independently of senescence 19 and apoptosis, that decreased when compared to controls (Supplementary Fig. 1d-i). Notably, *Pdha1* inactivation induced growth arrest exclusively in *Pten*^{-/-} MEFs, without altering the growth of *Pten*^{wt} MEFs (Supplementary Fig. 1g). Moreover, *Pdha1* deletion in *Pten* null tumours and MEFs did not affect the levels of pAkt at Ser 473 and the total amount of mitochondria as indicated by the protein levels of Voltage-dependent anion channel 1 (Vdac1) 5 (Fig. 1a, Supplementary Fig. 1j and uncropped blots in Supplementary Fig. 13).

Next, we assessed the status of both *PDHA1* and *PDP1* in human prostate cancers. Bioinformatics analysis revealed that both *PDHA1* and *PDP1* are frequently amplified at the gene level and over-expressed in human prostate tumours. Interestingly, *PDP1* was found amplified (3/3 available datasets) and overexpressed (9/11 datasets) in primary prostate tumours when compared to normal prostate tissues whereas *PDHA1* was found amplified (2/3 datasets) and overexpressed (7/13 datasets) (Supplementary Fig. 2a-e) in metastatic when compared to primary tumours. We also stained *PDHA1*, phospho-*PDHA1* and *PDP1* on a tissue microarray (TMA) consisting of 128 prostate carcinoma and normal prostate samples. Immunohistochemistry analyses revealed that both *PDHA1* and *PDP1* are frequently over-expressed in human prostate tumours and their expression increases in tumours with high Gleason score (Supplementary Fig. 3a-c). On the contrary, phospho-*PDHA1* staining was found upregulated only in a small portion of cases with a low Gleason score (Supplementary Fig. 3a,d). Interestingly the majority of cases having either high *PDP1* or *PDHA1* staining were negative for phospho-*PDHA1* (Supplementary Fig. 3e). Three out of four prostate cancer cell lines exhibited increased PDC activity compared to non-transformed PNT2C2 prostate cells (Supplementary Fig. 3f). This was associated with increased protein levels of both *PDHA1* and *PDP1* and enhanced mitochondrial oxygen consumption dependent on both glucose and glutamine utilization (Supplementary Fig. 3f-i and uncropped blots in Supplementary Fig. 14). Taken together these data demonstrate that in prostate tumours and in cancer cell lines the PDC is active.

We next inactivated *PDHA1* in prostate cancer cells by means of different *PDHA1* shRNAs. In agreement with the results in the mouse model, we found that inactivation of PDC resulted in inhibition of cellular proliferation independently of apoptosis (Fig. 1g and Supplementary Fig. 3j,k and uncropped blots in Supplementary Fig. 12). We also detected, decreased mitochondrial respiration in cells infected with sh*PDHA1* when compared to control (Supplementary Fig. 3l). Spheres forming ability in LNCaP, 22Rv1, and PC3 was also impaired upon *PDHA1* inactivation (Fig. 1h-j, Supplementary Fig. 3m and uncropped blots in Supplementary Fig. 14). 22Rv1 and PC3 prostate cancer cells, infected with sh*PDHA1* also formed smaller tumours *in vivo* than controls (Fig. 1k, l and uncropped blots in Supplementary Fig. 12).

***Pdha1* inactivation decreases mitochondrial intermediates**

Next, we performed metabolomics analysis in WT, *Pdha1*^{PC-/Y}, *Pten*^{PC-/} and *Pten*^{PC-/}; *Pdha1*^{PC-/Y} prostates. *Pten*^{PC-/} tumours presented signs of increased TCA cycle as measured by increased, citrate, α -ketoglutarate, acetyl CoA, ATP production and NADH levels (Supplementary Fig. 4a-d, Supplementary Table 4 and Supplementary Note). Increased extracellular lactate levels in *Pten* null MEFs also suggested increased glycolytic flux in these cells when compared to control (Supplementary Fig. 4e and Supplementary Note). *Pdha1* inactivation in *Pten* null tumours and MEFs resulted in decreased TCA cycle intermediates such as citrate and α -ketoglutarate and affected NADH/NAD⁺ ratio, ATP and acetyl-CoA levels (Supplementary Fig. 4a-f, Supplementary Table 4 and Supplementary Note). However, glycolysis and lactate production were not consistently affected (Supplementary Fig. 4a, e), in agreement with previous findings in different models^{20–22}. Of note, oxaloacetate levels significantly increased in compound mutant mice, in line with a block in the cycle due to loss of acetyl-CoA production downstream PDC (Supplementary Fig. 4a, d and Supplementary Table 4). To determine whether *Pdha1* inactivation induces changes in central carbon metabolism we measured stationary flux^{5,20} through TCA cycle in prostate epithelial cells derived from transgenic mice of different genotypes, using ¹³C-stable isotope labeled glucose, glutamine, and palmitate respectively. This analysis showed increased glucose and glutamine incorporation into citrate, fumarate, and malate in *Pten*^{PC-/} cells when compared to normal prostate epithelial cells. Glucose incorporation into citrate in *Pten*^{PC-/}; *Pdha1*^{PC-/Y} tumor cells, decreased (~70%) when compared to *Pten*^{PC-/} cells. Importantly, PDC inactivation led to compensatory oxidative glutaminolysis and to the production of acetyl-CoA from fatty acid β -oxidation for the reactivation of the TCA (reflected in a 30% increased citrate labeling from palmitate). This compensation, however, did not overcome the decreased citrate synthesis (Supplementary Fig. 4a and Supplementary Table 4). Surprisingly, glutaminolysis compensated the oxidative reactions after α -ketoglutarate to fumarate and malate until aspartate synthesis in TCA cycle. However, glutamine carbon pool was blocked from the reactions for citrate production probably due to the decreased expression of *Idh1* in *Pten*^{PC-/}; *Pdha1*^{PC-/Y} when compared to *Pten*^{PC-/} tumour cells (Supplementary Fig. 5d,g and Supplementary Table 5-7). Finally, the Pyruvate carboxylase activity did not change in response to *PDHA1* loss since the M+3 aspartate did not increase in *Pten*^{PC-/}; *Pdha1*^{PC-/Y} when compared to *Pten*^{PC-/} tumour cells (Supplementary Fig. 4g and and Supplementary Table 5). Taken together, these data

demonstrate that PDC inactivation reduces production of TCA intermediates and energetic yield in prostate tumours.

***Pdha1* knockdown induces tumour suppression by abrogating lipogenesis**

Pdha1 has been long defined as a mitochondrial metabolism regulator. However, recent evidence demonstrates that the PDC controls the nuclear pool of acetyl-CoA thereby promoting histone acetylation and regulating gene expression^{23,24}. In line with this evidence, we detected a strong nuclear localization of PDHA1 in *Pten*^{PC-/-} tumours and PDC activity in both the cytosol and nucleus of these tumour cells (see insets in Fig. 1d, Supplementary Figs. 1c and 5a,b and uncropped blots in Supplementary Fig. 14). We also detected *Pdha1*, *Dlat* and *Dld* in the nuclear fractions of *Pten*^{PC-/-} tumor cells (Supplementary Fig. 5c and uncropped blots in Supplementary Fig. 14). Transcriptomics followed by GSEA analysis in *Pten*^{PC-/-} and *Pten*^{PC-/-}; *Pdha1*^{PC-/Y} tumours demonstrated that fatty acid synthesis, cholesterol biogenesis and genes controlled by the sterol responsive element binding factor (SREBF)25–28 were the most downregulated pathways in *Pten*^{PC-/-}; *Pdha1*^{PC-/Y} tumours (Fig. 2a). Inactivation of *Pdha1* in *Pten*^{PC-/-} tumours and sh*PDHA1* human prostate cancer cells decreased Histone H3 Lysine 9 acetylation (H3K9Ac) thereby potentially affecting gene expression (Fig. 2b,c and uncropped blots in Supplementary Fig. 12). Notably, two rate-limiting enzymes engaging fatty acid synthesis and cholesterol biogenesis, ATP Citrate Lyase (*Acly*)^{29,30} and Squalene Epoxidase (*Sqle*)^{31,32} were strongly decreased in both *Pten*^{PC-/-}; *Pdha1*^{PC-/Y} tumours and sh*PDHA1* human prostate cancer cell lines at both protein and gene expression levels (Fig. 2b-f). Downregulation of *ACLY* in these cells was not associated with the upregulation of Acyl-coenzyme A synthetase short-chain family member 2 (*ACSS2*)^{33,34} (Fig. 2d,e). Genes that divert TCA cycle and glutamine intermediates into the lipid metabolisms^{22,35,36} were also downregulated by *PDHA1* inactivation in both mouse and human prostate tumour cells (Supplementary Fig. 5d-f). Importantly, acetate supplementation³⁰ in the culture media of 22Rv1 and PC3 infected with sh*PDHA1*, restored global H3K9Ac, *SQLE* and *ACLY* levels (Fig. 2c). Chromatin immunoprecipitation (ChIP) analysis demonstrated that H3K9Ac and the binding of SREBF1 on the promoters of *ACLY* and *SQLE* decreased in response to the *PDHA1* knockdown in human prostate cancer cells and this was restored by acetate supplementation (Supplementary Fig. 5h, i and Fig. 2g,h). Acetate supplementation restored cell growth in both *Pten*^{-/-}; *Pdha1*^{-/-Y} MEFs and sh*PDHA1* 22Rv1 and PC3 cells (Fig. 2i-k). Of note, we did not detect any changes in H3K9Ac on the promoter of two cell cycle regulators, E2F Transcription Factor 1 (*E2F1*) and Cyclin D1 (*CCND1*), demonstrating the specificity of the epigenetic regulation of PDC in cancer cells (Supplementary Fig. 5j,k). Interestingly, *ACLY* over-expression in prostate cell lines infected with sh*PDHA1* rescued the growth arrest induced by loss of *PDHA1* only in cells supplemented with citrate (Supplementary Fig. 5l-n and uncropped blots in Supplementary Fig. 14) in agreement with previous data³⁰.

We next performed a direct measurement of lipid species in mouse prostate tumours and human prostate cancer cell lines depleted of *PDHA1*. Of note, the majority of lipid species, including cholesterol ester were decreased in *Pten*^{PC-/-}; *Pdha1*^{PC-/Y} when compared to *Pten*^{PC-/-} tumours and in sh*PDHA1* 22Rv1 and PC3 cells when compared to control cells (Supplementary Fig. 6, Supplementary Table 8-11 and Supplementary Note). ¹⁴C tracking

experiments in sh-*PDHA1* 22Rv1 and PC3 cells demonstrated that glucose and glutamine incorporation into lipids and cholesterol (Supplementary Fig. 7a-e and Supplementary Note) were strongly affected when compared to controls whereas glucose and glutamine incorporation into proteins, remained unchanged (Supplementary Fig. 7f,g and Supplementary Note). *PDHA1* knockdown did not affect glucose uptake but induced a slight increase of glutamine uptake (Supplementary Fig. 7h, i and Supplementary Note). In agreement with these findings lipid droplets, a known readout of lipid production^{5,37}, were strongly reduced in both mouse and human xenograft tumours upon *PDHA1* inactivation (Fig. 3a-d and Supplementary Fig. 7j-o). To assess whether lipid metabolism is affected by *PDHA1* inactivation, we cultured sh-*PDHA1* 22Rv1 and PC3 cells in both the presence and absence of fatty acids and we found that fatty acids fully rescued the growth arrest induced by the *PDHA1* knockdown. This was associated with the restoration of lipid droplets in the same cells (Fig. 3e,f and Supplementary Note). Rescue of proliferation upon fatty acid supplementation occurs independently by H3K9 acetylation and reactivation of the expression of *ACLY* and *SQLE* (Supplementary Fig. 7p and uncropped blots in Supplementary Fig. 15). This data suggests that fatty acids were directly incorporated into lipids. Collectively, these data demonstrate that PDC activity is required for the proliferation of mouse and human prostate tumour cells and that inactivation of PDC drives tumour growth inhibition by affecting histone acetylation and the expression of genes controlling lipid metabolism.

Nuclear PDC regulates the expression of lipid biosynthesis genes independently of mitochondrial PDC

Cellular compartmentalization allows cells to carry out different metabolic reactions at the same time, and pathological protein compartmentalization is associated with cancer³⁸. We, therefore, dissected the role of nuclear and cytosolic PDC in prostate cancer, by expressing nuclear export signal (NES) and/or nuclear localization signal (NLS) fused *PDHA1* vectors in prostate cancer cell lines previously infected with (shRNA) and without *PDHA1* (sh*PDHA1*) (Fig. 4a, uncropped blots in Supplementary Fig. 13 and Supplementary Fig. 8a). NES-*PDHA1* and NLS-*PDHA1* constructs were engineered as sh*PDHA1* resistant vectors. Expressions of these vectors in 22Rv1 cells did not affect SREBF1 maturation and nuclear translocation (Supplementary Fig. 8a). Restoration of NLS-*PDHA1* in sh-*PDHA1* cells recovered H3K9Ac and the expression of fatty acid synthesis genes (Fig. 4b-d, Supplementary Fig. 8b for the full panel and uncropped blots in Supplementary Fig. 13,15), but did not rescue citrate levels, lipids content and cell growth both *in vitro* and *in vivo* (Fig. 4e-h and Supplementary Fig. 8c-g). In contrast, overexpression of both NES-*PDHA1* and NLS-*PDHA1* restored lipid synthesis genes, citrate levels, lipids content and cell growth (Fig. 4b-h and Supplementary Fig. 8b-g). Interestingly, the selective *ACLY* inhibitor, SB-204990 partially decreased H3K9 acetylation in prostate cancer cells with high PDC activity and SB-204990 did not further increase the growth arrest in prostate cancer cells infected with a shRNA against *PDHA1* (Supplementary Fig. 8h-j and uncropped blots in Supplementary Fig. 15). These data demonstrate that PDC can directly contribute to histone acetylation, independently by the regulation of *ACLY*³⁰. These experiments reveal that nuclear PDC regulates the expression of lipid synthesis gene in an autonomous manner and both nuclear and cytosolic *PDHA1* are needed for the proliferation of prostate cancer cells.

Nuclear PDC regulates fatty acid synthesis in presence of mitochondrial citrate

Consistently with these findings, we proved that overexpression of NLS-PDHA1 rescued growth arrest and lipid synthesis in cells cultured in the presence of citrate (Fig. 5a, b and Supplementary Fig. 9a for the whole panel). To validate these findings using an additional system, we overexpressed PDK1 in prostate cancer cells. Previous evidence demonstrates that PDK1 overexpression suppresses mitochondrial metabolism decreasing the intracellular levels of citrate without halting the nuclear function of PDC^{23,39–41}. In line with this evidence overexpression of PDK did not promote phosphorylation of nuclear PDHA1 (Supplementary Fig. 9b and uncropped blots in Supplementary Fig. 15). Overexpression of PDK1 in 22Rv1 cells decreased citrate levels and slightly suppresses cancer cell proliferation both *in vitro* and *in vivo* (Fig. 5c-e and Supplementary Fig. 8c-e). However, it did not decrease histone acetylation and expression of fatty acid synthesis genes (Fig. 5f, uncropped blots in Supplementary Fig. 13 and Supplementary Fig. 9b). In contrast, concomitant inactivation of *PDHA1* and overexpression of PDK1 decreased citrate level, histone acetylation and lipids content thereby suppressing tumourigenesis of a greater extent than in cells infected with PDK1 alone (Fig. 5c-f and Supplementary Fig. 9c-e). Taken together, these results demonstrate that both mitochondrial and nuclear PDC is required for prostate tumour growth.

Pharmacological inhibition of PDHA1 arrests mouse and human prostate tumours

Given that prostate cancer relies on PDC for proliferation we assessed whether pharmacological inhibition of PDHA1 could also block tumourigenesis in *Pten*^{PC-/-} tumours and human xenograft models of prostate cancer. We reasoned that a compound that could affect both the mitochondrial and nuclear function of PDC could be effective in blocking prostate cancer. To this extent, we took advantage of 3-fluoropyruvate (3-FP), a competitive inhibitor of the PDHA1^{42–45}. Computer simulations confirmed that 3-FP and pyruvate bind to PDHA1 with similar affinity (Supplementary Fig. 10a, b and Supplementary Note). To assess the specificity of 3-FP for the PDC, cell lysates treated with 3-FP were incubated in presence or absence of pyruvate. 3-FP decreased the activity of PDC and this was reversed by adding pyruvate in a dose dependent manner to the reaction buffer (Supplementary Fig. 10c). 3-FP administered by intraperitoneal injection in *Pten*^{PC-/-} mice inhibited the PDC activity *in vivo* in absence of systemic toxicity and induced a strong decrease of tumour cells proliferation as demonstrated by the reduced tumour size, tumour invasiveness and Ki-67 staining (Supplementary Fig. 10d-j). Importantly, 3-FP inhibited PDC both in the nucleus and the cytosol of prostate tumour cells and decreased H3K9Ac, Acly and Sqle levels *in vivo* at both protein and mRNA levels (Supplementary Fig. 10k-m and uncropped blots in Supplementary Fig. 15). Metabolomics analysis via LC-MS/MS⁴⁶ confirmed that 3-FP strongly affected pyruvate metabolism and TCA cycle (Supplementary Fig. 11a). Finally, lipids droplet staining showed a decreased percentage of the number, size and intensity of lipid bodies in *Pten*^{PC-/-} tumours treated with 3-FP (Supplementary Fig. 11b-e). 3-FP treatment blocked the proliferation of different human prostate cancer cells and this was associated with a decreased PDC activity (Supplementary Fig. 11f, g). Finally, 3-FP treatment decreased the proliferation of different human prostate cancer xenografts (LNCaP, 22Rv1 and PC3) promoting long-lasting anti-tumour responses *in vivo* (Supplementary Fig.

11h-j). Taken together these data suggest that pharmacological inactivation of PDC hampers prostate cancer progression.

Discussion

Whether the PDC acts as an oncogene or tumour suppressor in cancer is still under debate^{19,22,23,39,40,47–49}. A previous report shows that reduction in PDC activity through overexpression of PDK1 in melanoma cells promote tumour cell proliferation by enhancing glycolysis and reductive carboxylation¹⁹. In this and other models, activation of PDC by dichloroacetate promoted tumour suppression^{19,47}. Our data provide a new angle and demonstrate that the subunits of the PDC such as PDHA1 and PDP1 are amplified and overexpressed at both gene and protein levels and that the PDC is active in prostate cancer. In line with this evidence, we demonstrate that inactivation of *PDHA1* hampers prostate cancer progression *in vivo* in both mouse and human prostate cancer models. These findings are in agreement with recent studies demonstrating that tumor cells, *in vivo*, increased glucose oxidation via PDC. *PDHA1* inactivation in non-small lung cells cancer (NSCLC) xenografts resulted in a decreased tumor formation capacity. An increased TCA cycle via PDC was also observed in poorly perfused tumours areas of patients affected by NSCLC^{9,10,50}. These data, together with our data in prostate cancer, challenged the notion that tumours switch from glucose derived oxidative metabolism to aerobic glycolysis to support their growth⁶. However, the mechanisms by which tumour cells *in vivo* become addicted to PDC-mediated mitochondrial metabolisms still remain unknown. As suggested by previous studies this may be explained by the genetic background of the tumours, a difference in tissue requirements or in the composition of the tumour microenvironment¹⁰. Intriguingly normal prostate epithelial cells exhibit a “truncated” TCA cycle due to inhibition of aconitase needed for the production and secretion of a high quantity of citrate into the seminal fluid^{51–53}. Therefore, it is not surprising that prostate cancer relies on mitochondrial metabolism more than other tumour types.

Our results reveal that in order to support prostate cancer growth the PDC must be functional in both mitochondria and the nucleus of cancer cells. Mitochondrial PDC function is not sufficient to support lipid biosynthesis in tumour cells since nuclear PDC regulates the transcription of the enzymes that convert cytosolic citrate into acetyl-coA and fatty acids (Supplementary Fig. 11k, l). This compartmentalization allows the mitochondrial production of citrate in the cytosol and the expression of enzymes required for *de novo* lipid biosynthesis. Prior studies demonstrate that prostate cancer also benefits of enhanced glycolytic metabolism. However, these aggressive glycolytic tumour cells retain an active glucose-derived lipid biosynthesis⁵⁴, thus in line with the results presented herein.

Our findings also hold important implications for cancer therapy and pave the way for the targeting of the nuclear function of PDC to eradicate prostate cancer. This may be achieved in the future as shown in this paper by using pyruvate analogs or alternatively by developing small molecule inhibitors of PDHA1.

Online Methods

Animals

All mice were maintained under specific-pathogen-free conditions in the animal facilities of the IRB Institute, and experiments were performed according to state guidelines and approved by the local ethics committee. The *Pten*^{loxP} and *Pdha1*^{loxP} conditional knockout alleles have been described^{15,18}. Female *Pten*^{loxP/loxP}; *Pdha1*^{loxP/Y} mice were crossed with male *Probasin-Cre4* (*Pb-Cre4*) transgenic mice¹⁴ for the prostate-specific deletion of *Pten* and *Pdha1*. For genotyping, tail DNA was subjected to polymerase chain reaction analysis with the primers listed in Supplementary Table 1. Mice of correct genotypes were randomly chosen and allocated into experimental groups. For the transgenic mice, the experiment was carried on in single blind.

Cell culture and reagents

Human prostate carcinoma cell lines, 22Rv1, LNCaP, PC3, and DU145 were purchased from ATCC and human prostate epithelial PNT2C2 cell line⁵⁵ were gifted from Prof. Norman James Maitland, University of York and kept in Institute of Oncology Research (IOR) in Bellinzona, Switzerland. The cells were cultured in RPMI medium 1640 (Catalog# 21875034, Thermo Fisher Scientific) with 10% fetal bovine serum (FBS) (Catalog# 10500-064, Thermo Fisher Scientific), 10,000 I.U./mL Penicillin and 10,000 (µg/mL) Streptomycin (Catalog# P4333-20ML, Sigma) under the condition of 37 °C and 5% CO₂. Cells were transduced with TRIPZ doxycycline inducible lentiviral construct against human PDHA1 gene (Catalog# V2THS_75677, Dharmacon) and TRIPZ Inducible Lentiviral Empty Vector shRNA Control (Catalog# RHS4750, Dharmacon). Flat bottom ultra low attachment multiple well plates (Catalog# 3473, Corning) were used for sphere formation assay. Cells were transduced with pLKO lentiviral constructs against human *PDHA1* gene (Catalog# SHCLNG-NM_000284, Sigma, clone# sh*PDHA1*-1: TRCN0000028582 and sh*PDHA1*-2: TRCN0000028627) and Lentiviral Empty Vector shRNA Control (Catalog# SHC002, Sigma). PDHA1 was PCR-amplified from complementary DNA of a normal human prostate sample. For the overexpression of cytosol and nuclear-localized PDHA1, nuclear export signal (NES) or nuclear localization signal (NLS) was fused PDHA1 as NES-PDHA1 and NLS-PDHA1. NES-PDHA1 and NLS-PDHA1 constructs were engineered as sh-*PDHA1* (Catalog# SHCLNG-NM_000284, Sigma, clone# sh*PDHA1*-1: TRCN0000028582) resistant vectors. NES-PDHA1 and NLS-PDHA1 were cloned into pLenti CMV Neo (Addgene) and the empty vector was used as a control. Cells were infected shRNA control or sh*PDHA1* and overexpressed PDK1 by pLZRS-PDK1-IRES-puro or FG12-eGFP control¹⁹ (gifted from Prof. Daniel Peeper, The Netherlands Cancer Institute). Lentiviral and retroviral infections were performed using HEK293T cells and Phoenix cells, respectively, as producers of viral supernatants. Primary MEFs were derived from littermate embryos and obtained by crossing *Pdha1*^{loxP/loxP} or *Pten*^{loxP/loxP} animals. Embryos were harvested at 13.5 days post coitum, and individual MEFs were produced and cultured as previously described^{14–16}. For senescence experiments, MEFs were infected with pMSCV hygro-Cre (Plasmid #34565, Addgene) or empty vector control (pMSCV hygro) retrovirus, selected pharmacologically in hygromycin (50 µg/mL, Catalog# H0654-250MG, Sigma) for 48 hr. After selection, cells were seeded and analyzed for SA-β-gal activity (Catalog #9860,

Cell Signaling Technology). Cell number quantification with crystal violet was performed as referenced¹⁵. The chemicals used for cell and tumour treatments were purchased from Sigma: Doxycycline hyclate (Catalog# D9891-1G, Sigma) and β -Fluoropyruvic acid sodium salt monohydrate (3-Fluoropyruvate, 3-FP, Catalog #F4004, Sigma). SB-204990 (Catalog# 4962, Bio-Techne AG). For the xenograft experiments, 2×10^6 22Rv1 cells infected Tripz-sh*PDHA1* or Tripz-shRNA control were injected subcutaneously (s.c.) into the lower flank of the same nude mouse on different sides. The mice started to be fed with Doxycycline (0.2 g/L) water supplemented with 5% sucrose in another day. Tumour formation from each individual injection was monitored every three days until the 22nd day of experimental termination. 2×10^6 22Rv1 cells infected shRNA control or sh*PDHA1* and overexpressed PDK1 by pLZRS-PDK1-IRES-puro or FG12-eGFP control¹⁹ (gifted from Prof. Daniel Peeper, The Netherlands Cancer Institute) were injected subcutaneously (s.c.) into the lower flank of the same nude mouse on different sides. Tumour formation from each individual injection was monitored every three days until the 30th day of experimental termination. For experiments with xenograft, mice were excluded when the tumour size exceeded the average tumour size at the moment of randomization. The experiments with Xenograft (including tumour measurements) were carried on in single blind. For preclinical treatment on *Pten*^{pc/-} males, 80 mg/Kg of 3-FP were intraperitoneally injected every three days on mice of ages at 8 weeks to 12 weeks. For the xenograft tumours treated with 3-FP or vehicle control, 2×10^6 LNCaP, PC3, and 22Rv1 cells were injected subcutaneously (s.c.) into the lower flank of the nude mice. The treatment started when tumour size reached 100 mm³ and the treatment continued for a period of two months. When the mice were sacrificed, tumours were dissected and analyzed. Mice were fasted for 6 h prior to tissue harvest (9 am-3 pm) in order to prevent metabolic alterations due to immediate food intake.

Real-time PCR, western blotting, and immunohistochemistry

RNA was extracted using TRIzol® Plus RNA Purification Kit (Catalog# 12183555, Life technologies). 1 μ g of total RNA was used for cDNA synthesis using SuperScript® III Platinum® One-Step qRT-PCR Kit (Catalog# 11732-020, Life technologies). Quantitative Real Time PCR (q-RT PCR) was performed as previously described¹⁵. Primers employed are detailed in Supplementary Table 2. All qRT-PCR data presented was normalized using β -actin. Tissue and cell lysates were prepared with RIPA buffer (1 $\times$ PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail (Catalog# 78429, Thermo Scientific)). The following antibodies were used for western blotting: rabbit polyclonal anti-Pten antibody (Catalog # 9552, Cell Signaling Technology), mouse monoclonal anti-PDHA1 antibody (Catalog # 459400, Invitrogen), rabbit polyclonal anti-phospho-PDHE1-A type I (Ser293) antibody (Catalog# ABS204, EMD Millipore), goat polyclonal anti-PDC-E2 Antibody (N-20) (Catalog# sc-16890, Santa Cruz Biotechnology), mouse monoclonal anti-DLD Antibody (E-3) (Catalog# sc-376890, Santa Cruz Biotechnology), rabbit polyclonal anti-PDP1 antibody (Catalog# HPA019081, Sigma), rabbit polyclonal anti-Akt antibody (Catalog# 9272, Cell Signaling Technology), rabbit monoclonal anti-p-Akt Ser473 antibody (Catalog# 4060, Cell Signaling Technology), rabbit monoclonal anti-Acetyl-Histone H3 (Lys9) antibody (Catalog# 9649, Cell Signaling Technology), rabbit monoclonal anti-Histone H3 antibody (Catalog# 4499, Cell Signaling Technology), rabbit polyclonal anti-ACLY antibody (Catalog# 4332, Cell Signaling Technology), goat polyclonal anti-SQLE

antibody (Catalog# sc-49754, Santa Cruz Technology), rabbit monoclonal anti-VDAC1 (Catalog# 4661, Cell Signaling Technology), rabbit polyclonal anti- α -Tubulin antibody (Catalog# 2144, Cell Signaling Technology) and mouse monoclonal anti- β -actin (Catalog# A5316, Sigma). For immune-histochemistry (IHC), tissues were fixed in 10% formalin and embedded in paraffin in accordance with standard procedures. Sections were stained with Rabbit polyclonal anti-PTEN antibody (Catalog# 51-2400, Thermo Fisher Scientific), mouse monoclonal anti-PDHA1 (Catalog# 459400, Invitrogen), rabbit polyclonal Anti-PDP1 (Catalog# HPA019081, Sigma), anti-Ki-67 (clone SP6, Lab Vision), or anti-cleaved-caspase-3 (Catalog#9661, Cell Signaling Technology) antibodies. Prostate disease spectrum tissue array, including TNM, clinical stage and pathology grade, 80 cases/80 cores were purchased from US Biomax, Inc, (Catalog# PR8011a) and prostate cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/48 cores was purchased from US Biomax, Inc (Catalog# PR483b). Ki-67 and gland invasiveness assessment was performed by three prostate pathologists independently, in a blinded manner.

Gene Expression Analysis

Gene expression profiling (GEP) was done using the MouseRef-8 v2.0 Expression BeadChip (Illumina, San Diego, CA, USA), following the manufacturer's protocol. Arrays were read on an Illumina HiScanSQ system. Data were first extracted with the Illumina GenomeStudio software and then imported in Genomics Suite 6.4 (Partek Incorporated, Saint Louis, MO USA) and quantile normalized. Transcripts with differences in expression were identified by ANOVA. Enrichment analysis was performed using Gene Set Enrichment Analysis (GSEA) 56. Raw data have been deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GEO) and are accessible through GEO accession no. GSE74245. GSEA was performed on entire gene list ranked according to fold changes observed between *Pten*^{pc/-} and *Pten*^{pc/-}; *Pdha1*^{pc/Y} mice. The GS collection assessed includes all GSs smaller than 10 and larger than 500 (8335 out of 22423 GSs retained) compiled according to 57 the 24.03.15. GSs yielding significance ((FDR <0.05; nominal p-value <0.005; TAGS $\geq$ 50%) were retained and assessed for their role in metabolic processes after visualizing the data as described 58. For the 3 relevant clusters identified, their GSs' FDR q-values were, together with unaffected metabolic processes log2 transformed and inverted for display in Fig. 2a.

Chromatin immunoprecipitation

ChIP assays were performed with approximately 6×10^6 cells per experiment. Cells were subject to hypotonic lysis and treated with micrococcal nuclease to recover mono- to tri-nucleosomes. Nuclei were lysed by brief sonication and dialysed into N-ChIP buffer (10 mM Tris pH 7.6, 1 mM EDTA, 0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100) for 2 h at 4 °C. Soluble material was incubated overnight at 4 °C after addition of 0.5–1 μ g of antibody bound to 25 μ l protein A Dynal magnetic beads (Catalog# 10006D, Invitrogen), with 5% kept as input DNA. Magnetic beads were washed, chromatin was eluted and ChIP DNA was dissolved in 10 mM Tris pH 8 for quantitative PCR reactions (see later). Three separate ChIP experiments were performed on replicate biological samples. The data shown are the average qRT-PCR values (n =3). Primers are listed below. All qPCR was performed using an Applied Biosystems StepOnePlus system and Power SYBR Green PCR master

mix. ChIP samples were diluted 1:100 in H₂O and 5 µl was used per reaction. ChIP-qPCR signals were calculated as per cent input. Primers used in ChIP were listed in Supplementary Table 3.

Subcellular fractionation

Nuclear and cytoplasmic fractionation was performed by centrifugation technique as described previously⁵⁹. Nuclear and cytoplasmic extracts were made using NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Catalog# 78833, Pierce Biotechnology). Total cell lysate was prepared in radioimmunoprecipitation assay buffer (RIPA; 25 mmol/L Tris (pH 7.4), 150 mmol/L KCl, 5 mmol/L EDTA, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS) with protease inhibitor cocktail (Catalog# 88688, Thermo Scientific). Proteins at the same amount were separated by 10% to 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. For each fraction, nuclear protein histone 3 (Catalog# 4499, Cell Signaling Technology) and cytoplasmic protein α -Tubulin (Catalog# 2144, Cell Signaling Technology) were used to show clear isolation between nucleus and cytoplasm during fractionation.

Targeted mass spectrometry analysis

For mouse prostate tissues, 500 µL of 80% LC-MS grade methanol was added to each approximately 15 mg sample and incubated at -80°C for 15 min. Tissue samples collected were centrifuged at 18,470g for 5 min in a cold room to pellet cell debris and proteins. Supernatants were saved. Pellets were resuspended in 500 µl 80% methanol by vortexing and subsequently centrifuged as before. Supernatants were centrifuged one final time at 18,470g for 10 min at 4°C. Metabolite extractions were dried to a pellet by SpeedVac with no heat. Samples were re-suspended using 20 µL LC-MS grade water and 10 µL was injected and analyzed using a 5500 QTRAP hybrid triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) through selected reaction monitoring (SRM). Two hundred and sixty-one endogenous water-soluble metabolites were targeted for steady-state analyses of samples. Some metabolites were targeted in both the positive and negative ion mode through a positive/negative polarity switching for a total of 296 SRM transitions. The ESI voltage was +4900V in the positive ion mode and -4500V in the negative ion mode. The dwell time was 3ms per SRM transition and the total cycle time was ~1.56 sec. Approximately 10-12 data points were acquired per detected metabolite. Samples were delivered to the MS through normal-phase chromatography using a 4.6mm i.d ×10 cm Amide XBridge HILIC column (Waters Corp.) at 350 µl min⁻¹. Gradients were run starting from 85% buffer B (HPLC grade acetonitrile) to 35% B from 0-3.5 min; 35% B to 2% B from 3.5-11.5 min; 2% B was held from 11.5-16.5 min; 2% B to 85% B from 16.5-17.5 min; 85% B was held for 7 min to re-equilibrate the column. Buffer A was comprised of 20mM ammonium hydroxide/20mM ammonium acetate (pH 9.0) in 95:5 water/acetonitrile. Peak areas from the total ion current for each metabolite SRM transition were integrated using MultiQuant v2.1 software (AB/SCIEX). Metabolomics data analysis was done in part using Metaboanalyst 2.0 software (www.metaboanalyst.ca).

Isotope Labeling and stationary Profiling

Fresh transgenic mouse tumour tissues were mechanically dissociated, enzymatically digested and filtered to obtain a single-cell suspension as described⁶⁰. Single cells were stained with fluorescein isothiocyanate (FITC)-anti-CD34 (Catalog# 560238, BD Biosciences) for stroma cells, FITC-anti-Ter119 (Catalog# 557915, BD Biosciences) for erythrocytes, FITC-anti-CD31 (Catalog# 561813, BD Biosciences) for endothelial cells, and FITC-anti-CD45 (Catalog# 553079, BD Bioscience) for leukocytes and incubated 20 min on ice. All antibodies (BD Biosciences) were used at 1:300; cells were then loaded into MS column with Anti-FITC MicroBeads (Catalog# 130-048-701, Miltenyi Biotec) for MACS separation, and unstained epithelial cells were collected in the negative fraction. For steady state metabolomic analysis⁵, prostate epithelial cells derived from transgenic mouse tumours were plated to ~80% confluence on 10 cm dishes in biological quadruplicate. cells were plated in RPMI medium (Catalog# 11875093, Thermo Scientific) was supplemented with 10% dialyzed serum and devoid of glucose or glutamine and supplemented with one of the two carbon-13-labelled substrates [U-¹³C₆]-glucose and [U-¹³C₅] glutamine (Catalog# CLM-1396-1 and CLM-1822-H-0.25, Cambridge Isotope Labs) where the remaining substrates were unlabelled (glucose 11 mM and glutamine 2 mM). Fatty acid oxidation studies²⁰ were conducted using [U-¹³C₁₆] palmitate (Catalog# CLM-6059-1, Cambridge Isotope Labs) noncovalently bound to fatty acid-free BSA. [U-¹³C₁₆] palmitate-BSA was added to culture medium at 5% of the final volume (50 mM final concentration) with 1 mM carnitine in medium formulated with delipidated FBS (Catalog# 12676011, Thermo scientific). Additionally, fresh media containing carbon-13-labelled substrates was exchanged 2 h prior to metabolite extraction for steady state analyses. Considering primary epithelial cells isolated from mouse prostate tissue do not attach and fit for long term culture, we labeled these epithelial cells for 6 h and we did not see the difference compared to the results from labeling for 24 h. After 6 h of incubation with labelled substrates, metabolite extraction of medium was performed by adding 1mL cold (−80 °C) 80% methanol (Catalog#34966-1L and 14263-1L, Sigma), incubated at −80 °C for 30 min followed by centrifugation at 10,000g for 10 min at 4 °C. The resultant supernatant was lyophilized by speedvac and stored at −80 °C until analysis. Dried metabolite pellets were re-suspended in 20 µL LC–MS grade water, 5 µL was injected onto a Prominence UFLC and separated using a 4.6 mm i.d. Å~ 100 mm Amide XBridge HILIC column at 360 µL per minute starting from 85% buffer B (100% ACN) to 0% B over 16 min. Buffer A: 20 mM NH₄OH/20 mM CH₃COONH₄ (pH = 9.0) in 95:5 water/ACN.²⁸⁷ selected reaction monitoring (SRM) transitions were captured using positive/ negative polarity switching by targeted LC-MS/MS using a 5500 QTRAP hybrid triple quadrupole mass spectrometer. As for metabolomics, the quantity of the metabolite fraction analyzed was adjusted to the corresponding protein concentration from a sample processed in parallel. The analysis was performed for each of the three substrates on three independent tumours in biological triplicate.

Lipidomics analysis on transgenic mouse prostate tumours

~ 5 mg of solid tissue was snap frozen in liquid nitrogen (−196°C) as close to the time of resection as possible. Chloroform: methanol (2:1 ratio) was added to a final volume 20 times the volume of the biological sample (100 µL in 2 mL of solvent mixture) in a 12 mL glass vial. The mixture was agitated for 30 min in an orbital shaker at room temperature. 0.2

volume parts of water (400 μ L for 2 mL) was added and the mixture was vortexed for 1 min. The mixture was placed still for 10 min and centrifuge at low speed (1000 g) to separate into three phases. The upper aqueous phase was kept (optional) to analyze small organic polar molecules. The middle layer contains protein, DNA, and polar large molecules. The lower phase containing non-polar lipids was collected and evaporated under vacuum using a SpeedVac rotary evaporator or under a nitrogen stream. 10 μ L of sample was injected onto LC-MS/MS using a hybrid QExactive Plus Orbitrap mass spectrometer in DDA mode using positive/negative ion polarity switching (Top 8 in both modes). Using a 100 mm x 2.0 mm C18 column at 260 μ L/min with a 1100 quaternary HPLC, lipids were eluted over 20 min. from 32% B buffer (90% IPA/10% ACN/10 mM NH_4HCO_2 /0.1% FA) to 97% B. A buffer consisted of 59.9% ACN/40% water/10 mM NH_4HCO_2 /0.1% FA. Lipid molecules were identified and quantified using LipidSearch 4.1.9 software⁶¹.

Statistics

For each independent *in vitro* experiment, at least three technical replicates were used (exceptions: in western blot analysis technical replicates are presented, in targeted metabolomics three technical replicates were used. For data mining analysis, ANOVA test was used for multi-component comparisons and Student T test for paired-comparisons. In the *in vitro* experiments, data groups were assessed for normal distribution and Student T test was applied for paired-comparison. Data represent mean $\pm$ s.e.m. of pooled experiments unless otherwise stated. n values represent the number of experimental samples and all the experiments were repeated at least three times. For *in vivo* experiments, the equal variance could not be assumed and a non-parametric Mann-Whitney test was used. The confidence level used for all the statistical analyses was of 0.95 (alpha value = 0.05). Two-tail statistical analysis was applied for experimental design without predicted result, and one-tail for validation experiments (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$).

Data availability

The mouse gene expression datasets are available at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74245>

For cellular, molecular and metabolic assays, the lipidomics analysis on prostate cancer cell line, fatty acid rescue assay and computer simulations of 3-FP and PDC docking, the methods are available in Supplementary Note.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors all the members of the IOR/IRB animal core facility for technical assistance and the animal work. We thank Min Yuan and Susanne B. Breitkopf for help with metabolomics analysis. The mass spectrometry work was partially supported by NIH grants P01-CA120964 (J.M.A.) and P30-CA006516 (J.M.A.). Cholesterol measurement in prostate cancer cell lines were supported by AIRC Investigator Grant (IG 2016 Id. 19104) and CARIPARO Pediatric research Grant. The work of A.M. was funded by Fondazione Umberto Veronesi and Associazione Italiana Ricerca sul Cancro and Fondazione Cassa di Risparmio di Firenze (grant 19515 to PC and AM) and AIRC (grant 8797 to PC). We thank Eugenio Ragazzi in Department of Pharmaceutical and Pharmacological Sciences,

University of Padova for the multivariate statistical analysis. The work of A.C. is supported by the department of education of the Basque Government (IKERTALDE IT1106-16), the BBVA foundation, the MINECO (SAF2016-79381-R (FEDER/EU); Severo Ochoa Excellence Accreditation SEV-2016-0644) and the European Research Council (Starting Grant 336343, PoC 754627). The participation of A.C. as part of CIBERONC was co-funded with FEDER funds. This work was supported by Swiss national science foundation (SNF) grant Ambizione (PZ00P3_136612/1), European Research Council starting grant (ERCsg 261342), the European Society for Medical Oncology (ESMO) translational research award to A.A., the Dr. Josef Steiner Cancer Research Award and the Swiss Bridge Award to A.A., and Fondazione IBSA fellowship award to J.C.

References

1. Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. *Mol Cell*. 2016; 61:667–676. DOI: 10.1016/j.molcel.2016.02.011 [PubMed: 26942671]
2. LeBleu VS, et al. PGC-1 α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nat Cell Biol*. 2014; 16:992–1003. DOI: 10.1038/ncb3039 [PubMed: 25241037]
3. Marin-Valencia I, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. *Cell Metab*. 2012; 15:827–837. DOI: 10.1016/j.cmet.2012.05.001 [PubMed: 22682223]
4. Vazquez F, et al. PGC1 α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. *Cancer Cell*. 2013; 23:287–301. DOI: 10.1016/j.ccr.2012.11.020 [PubMed: 23416000]
5. Viale A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. *Nature*. 2014; 514:628–632. DOI: 10.1038/nature13611 [PubMed: 25119024]
6. Ahn CS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. *Cancer Metab*. 2015; 3:1.doi: 10.1186/s40170-015-0128-2 [PubMed: 25621173]
7. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. *Nat Chem Biol*. 2015; 11:9–15. DOI: 10.1038/nchembio.1712 [PubMed: 25517383]
8. Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. *Cell*. 2016; 166:555–566. DOI: 10.1016/j.cell.2016.07.002 [PubMed: 27471965]
9. Hensley CT, et al. Metabolic Heterogeneity in Human Lung Tumors. *Cell*. 2016; 164:681–694. DOI: 10.1016/j.cell.2015.12.034 [PubMed: 26853473]
10. Davidson SM, et al. Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. *Cell Metab*. 2016; 23:517–528. DOI: 10.1016/j.cmet.2016.01.007 [PubMed: 26853747]
11. Wieland OH. The mammalian pyruvate dehydrogenase complex: structure and regulation. *Rev Physiol Biochem Pharmacol*. 1983; 96:123–170. [PubMed: 6338572]
12. Kolobova E, Tuganova A, Boulatnikov I, Popov KM. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. *Biochem J*. 2001; 358:69–77. [PubMed: 11485553]
13. Roche TE, et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. *Prog Nucleic Acid Res Mol Biol*. 2001; 70:33–75. [PubMed: 11642366]
14. Trotman LC, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol*. 2003; 1:E59.doi: 10.1371/journal.pbio.0000059 [PubMed: 14691534]
15. Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature*. 2005; 436:725–730. DOI: 10.1038/nature03918 [PubMed: 16079851]
16. Alimonti A, et al. Subtle variations in Pten dose determine cancer susceptibility. *Nat Genet*. 2010; 42:454–458. DOI: 10.1038/ng.556 [PubMed: 20400965]
17. Wu X, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech Dev*. 2001; 101:61–69. [PubMed: 11231059]
18. Johnson MT, et al. Inactivation of the murine pyruvate dehydrogenase (Pdha1) gene and its effect on early embryonic development. *Mol Genet Metab*. 2001; 74:293–302. DOI: 10.1006/mgme.2001.3249 [PubMed: 11708858]
19. Kaplon J, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. *Nature*. 2013; 498:109–112. DOI: 10.1038/nature12154 [PubMed: 23685455]

20. Vacanti NM, et al. Regulation of substrate utilization by the mitochondrial pyruvate carrier. *Mol Cell*. 2014; 56:425–435. DOI: 10.1016/j.molcel.2014.09.024 [PubMed: 25458843]
21. Yang C, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. *Mol Cell*. 2014; 56:414–424. DOI: 10.1016/j.molcel.2014.09.025 [PubMed: 25458842]
22. Rajagopalan KN, et al. Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells. *Cancer Metab*. 2015; 3:7.doi: 10.1186/s40170-015-0134-4 [PubMed: 26137220]
23. Sutendra G, et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. *Cell*. 2014; 158:84–97. DOI: 10.1016/j.cell.2014.04.046 [PubMed: 24995980]
24. Nagaraj R, et al. Nuclear Localization of Mitochondrial TCA Cycle Enzymes as a Critical Step in Mammalian Zygotic Genome Activation. *Cell*. 2017; 168:210–223 e211. DOI: 10.1016/j.cell.2016.12.026 [PubMed: 28086092]
25. Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. *J Biol Chem*. 1993; 268:14490–14496. [PubMed: 8390995]
26. Wang X, et al. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization. *J Biol Chem*. 1993; 268:14497–14504. [PubMed: 8314806]
27. Porstmann T, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab*. 2008; 8:224–236. DOI: 10.1016/j.cmet.2008.07.007 [PubMed: 18762023]
28. Han J, et al. The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. *Nature*. 2015; 524:243–246. DOI: 10.1038/nature14557 [PubMed: 26147081]
29. Hatzivassiliou G, et al. ATP citrate lyase inhibition can suppress tumor cell growth. *Cancer Cell*. 2005; 8:311–321. DOI: 10.1016/j.ccr.2005.09.008 [PubMed: 16226706]
30. Wellen KE, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. *Science*. 2009; 324:1076–1080. DOI: 10.1126/science.1164097 [PubMed: 19461003]
31. Helms MW, et al. Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. *Br J Cancer*. 2008; 99:774–780. DOI: 10.1038/sj.bjc.6604556 [PubMed: 18728668]
32. Stevenson J, Luu W, Kristiana I, Brown AJ. Squalene mono-oxygenase, a key enzyme in cholesterol synthesis, is stabilized by unsaturated fatty acids. *Biochem J*. 2014; 461:435–442. DOI: 10.1042/BJ20131404 [PubMed: 24840124]
33. Zhao S, et al. ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch. *Cell Rep*. 2016; 17:1037–1052. DOI: 10.1016/j.celrep.2016.09.069 [PubMed: 27760311]
34. Bulusu V, et al. Acetate Recapturing by Nuclear Acetyl-CoA Synthetase 2 Prevents Loss of Histone Acetylation during Oxygen and Serum Limitation. *Cell Rep*. 2017; 18:647–658. DOI: 10.1016/j.celrep.2016.12.055 [PubMed: 28099844]
35. Metallo CM, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. *Nature*. 2012; 481:380–384. DOI: 10.1038/nature10602
36. Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature*. 2012; 481:385–388. DOI: 10.1038/nature10642
37. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. *Cell Metab*. 2013; 18:153–161. DOI: 10.1016/j.cmet.2013.05.017 [PubMed: 23791484]
38. Aguzzi A, Altmeyer M. Phase Separation: Linking Cellular Compartmentalization to Disease. *Trends Cell Biol*. 2016; 26:547–558. DOI: 10.1016/j.tcb.2016.03.004 [PubMed: 27051975]
39. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab*. 2006; 3:177–185. DOI: 10.1016/j.cmet.2006.02.002 [PubMed: 16517405]
40. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab*. 2006; 3:187–197. DOI: 10.1016/j.cmet.2006.01.012 [PubMed: 16517406]

41. Dupuy F, et al. PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. *Cell Metab.* 2015; 22:577–589. DOI: 10.1016/j.cmet.2015.08.007 [PubMed: 26365179]
42. Mager J, Blank I. Synthesis of fluoropyruvic acid and some of its biological properties. *Nature.* 1954; 173:126–127. [PubMed: 13132885]
43. Avi-Dor Y, Mager J. The effect of fluoropyruvate on the respiration of animal-tissue preparations. *Biochem J.* 1956; 63:613–618. [PubMed: 13355859]
44. Chari-Bitron A, Avi-Dor Y. Effect of fluoropyruvate on the swelling, phosphorylative activity and respiration of guinea-pig liver mitochondria. *Biochem J.* 1959; 71:572–578. [PubMed: 13638267]
45. Du J, et al. Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. *J Biol Chem.* 2013; 288:36129–36140. DOI: 10.1074/jbc.M113.507285 [PubMed: 24187136]
46. Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. *Nat Protoc.* 2012; 7:872–881. DOI: 10.1038/nprot.2012.024 [PubMed: 22498707]
47. Hitosugi T, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. *Mol Cell.* 2011; 44:864–877. DOI: 10.1016/j.molcel.2011.10.015 [PubMed: 22195962]
48. Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. *Nature.* 2016; 531:110–113. DOI: 10.1038/nature16967 [PubMed: 26909577]
49. Bonnet S, et al. A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. *Cancer Cell.* 2007; 11:37–51. DOI: 10.1016/j.ccr.2006.10.020 [PubMed: 17222789]
50. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science.* 2009; 324:1029–1033. DOI: 10.1126/science.1160809 [PubMed: 19460998]
51. Costello LC, Franklin RB. Aconitase activity, citrate oxidation, and zinc inhibition in rat ventral prostate. *Enzyme.* 1981; 26:281–287. [PubMed: 7308179]
52. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. *J Biol Chem.* 1997; 272:28875–28881. [PubMed: 9360955]
53. Costello LC, Liu Y, Zou J, Franklin RB. The pyruvate dehydrogenase E1 alpha gene is testosterone and prolactin regulated in prostate epithelial cells. *Endocr Res.* 2000; 26:23–39. [PubMed: 10711720]
54. Torrano V, et al. The metabolic co-regulator PGC1alpha suppresses prostate cancer metastasis. *Nat Cell Biol.* 2016; 18:645–656. DOI: 10.1038/ncb3357 [PubMed: 27214280]
56. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005; 102:15545–15550. DOI: 10.1073/pnas.0506580102 [PubMed: 16199517]
57. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. *PLoS One.* 2010; 5:e13984.doi: 10.1371/journal.pone.0013984 [PubMed: 21085593]
58. Delaleu N, Nguyen CQ, Tekle KM, Jonsson R, Peck AB. Transcriptional landscapes of emerging autoimmunity: transient aberrations in the targeted tissue's extracellular milieu precede immune responses in Sjogren's syndrome. *Arthritis Res Ther.* 2013; 15:R174.doi: 10.1186/ar4362 [PubMed: 24286337]
59. Zhao J, et al. TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. *Cancer Res.* 2008; 68:4133–4141. DOI: 10.1158/0008-5472.CAN-08-0432 [PubMed: 18519672]
60. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. Isolation, cultivation and characterization of adult murine prostate stem cells. *Nat Protoc.* 2010; 5:702–713. DOI: 10.1038/nprot.2010.11 [PubMed: 20360765]

61. Breitkopf SB, et al. A relative quantitative positive/negative ion switching method for untargeted lipidomics via high resolution LC-MS/MS from any biological source. *Metabolomics*. 2017; 13doi: 10.1007/s11306-016-1157-8





Figure 1. *Pdha1* knockout induces tumour suppression in mice and human prostate tumours. **(a)** Western blot analysis of indicated proteins in wild type, *Pdha1^{PC/Y}*, *Pten^{PC/-}* and *Pten^{PC/-}; Pdha1^{PC/Y}* prostates and tumours (n=3, independent prostate samples). Uncropped images are in Supplementary Figure 12. **(b)** Upper panel, PDC activity measurement in wild type, *Pdha1^{PC/Y}*, *Pten^{PC/-}* and *Pten^{PC/-}; Pdha1^{PC/Y}* prostates and tumours (n=3, independent prostate samples). Lower panel, Quantification of indicated proteins normalized to wild type tissues in indicated prostate tumours in **(a)** (n=3, independent prostate samples). **(c)** Comparison of anterior prostate (AP) lobe volumes (mm³, 2 independent lobes per animal

are presented) from male of indicated ages and genotypes between wild type, *Pdha1^{PC-/Y}*, *Pten^{PC-/Y}* and *Pten^{PC-/Y}; Pdha1^{PC-/Y}* prostate and tumours (N, the number of mice of indicated ages). Inset is the representative image of anterior prostate lobes in the panel. **(d)** Representative micrographs in histopathological analysis (haematoxylin/eosin staining and indicated proteins) of anterior prostates (AP) in *Pdha1^{PC-/Y}*, *Pten^{PC-/Y}* and *Pten^{PC-/Y}; Pdha1^{PC-/Y}* prostate tissues from 12 weeks old male mice (n=3) (Scale bar represents 50 μ m, insets are regions shown in higher magnification, see also Supplementary Fig. 1c for all the genotypes and images of lower magnification). **(e,f)** Quantification of the percentage of Ki-67 positive cells **(e)** and invasive prostate glands **(f)** in prostates from mice of indicated genotypes at different ages (N, number of mice of indicated ages). **(g)** Relative cell number quantification by crystal violet staining in the indicated prostate cancer cell lines infected with sh*PDHA1* or scramble control. Data is normalized to shRNA control. *PDHA1* inhibition validated by western blot analysis using two different sh*PDHA1* was shown in the inset of the panel. Uncropped images are in Supplementary Figure 12. (n=3, independent cell cultures). **(h)** Spheroid Formation Assays in LNCaP, 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-sh*PDHA1* or scramble control (n=3, independent cell cultures). Scale bar represents 50 μ m. **(i,j)** Quantification of spheroid diameter **(i)** and spheroid number per 500 cells **(j)** in LNCaP, 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-sh*PDHA1* or scramble Tripz-shRNA control (n=3, independent cell cultures). **(k,l)** Evaluation of tumour formation in xenotransplantation experiments of 22Rv1 **(k)** and PC3 **(l)** cells infected with indicated sh*PDHA1* or scramble shRNA control. The knockdown of *PDHA1* in 22Rv1 and PC3 xenograft tumours is validated by western blot in the inset of panel **(k)**. Uncropped images are in Supplementary Figure 12. (n=6 animals; 12 independent tumour samples). Error bars indicate s.e.m. ***P* < 0.01; ****P* < 0.001. n.s, not significant.



of indicated proteins in 22Rv1 cells infected with doxycycline-induced Tripz-sh*PDHA1* or scramble control and treated with 100 μ M acetate or vehicle over a 6-day period. Uncropped images are in Supplementary Figure 12. (n=3, independent cell cultures). **(d)** Upper panel, GSEA of SREBF target genes in *Pten*^{pc-/-}; *Pdha1*^{pc-/Y} versus *Pten*^{pc-/-} prostate tumours. Normalized enriched scores (NES) are presented. Data are mean $\pm$ standard deviation (s.d.). Lower panel, quantitative real time-PCR analysis of mRNA expression of indicated SREBFs and target genes and genes in acetyl CoA compensatory pathways in mouse prostate and tumours the indicated genotypes (n=3). **(e)** Quantitative real time-PCR analysis of mRNA expression of indicated SREBFs and target genes and genes in acetyl coA compensatory pathways in 22Rv1 cells infected with sh*PDHA1* and scramble shRNA control (n=3, independent cell cultures). **(f)** Quantitative RT-PCR analysis of *ACLY* and *SQLE* in 22Rv1 cells infected with doxycycline-induced Tripz-sh*PDHA1* or scramble control and treated with acetate (100 μ M) or vehicle for 6 days (n=3, independent cell cultures). **(g,h)** Chromatin immunoprecipitation analysis showing the binding of SREBF1 and H3K9Ac on the promoters of *ACLY* **(g)** and *SQLE* **(h)** in 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-sh*PDHA1* or scramble control and treated with 100 μ M acetate or vehicle over a 6-day period (n=3, independent cell cultures). **(i-k)** Relative cell number quantification by crystal violet staining of *Pten*^{-/-} and *Pten*^{-/-}; *Pdha1*^{-/-Y} MEFs **(i)** and human cancer cells 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-sh*PDHA1* or scramble control. **(j,k)** and treated with acetate (100 μ M) or vehicle over a 6-day period (n=3, independent cell cultures). Error bars indicate s.e.m. **P* < 0.05; ***P* < 0.01; ****P* < 0.001. n.s, not significant.




Figure 3. *Pdh1* knockdown induces tumour suppression by abrogating lipogenesis.

(a,b) Representative confocal images (a) and quantification of average lipid droplets per cell (Lipidtoxin, red) (b) in the indicated genotypes in *Pten^{pc/-}*; *Pdh1^{pc/-Y}* versus *Pten^{pc/-}* prostate tumours. DAPI, blue. (n=3 mice, Scale bar: 20 μ m, 1 tumour per mouse, 5 fields acquired). (c,d) Representative confocal images (c) and quantification of average lipid droplets per cell (Lipidtoxin, red) (d) in 22Rv1 and PC3 shPDHA1 and shRNA xenograft tumours. DAPI, blue. (n=3 mice, Scale bar represents 20 μ m, 1 tumour per mouse, 5 fields acquired). (e,f) Relative cell number quantification by crystal violet staining (e) and

quantification of lipid droplets by average lipid droplet per cell (**f**) in 22Rv1 and PC3 cells infected with a sh*PDHA1* and scramble shRNA control and treated with exogenous fatty acids in fatty acid free media; oleate (25 μ M), palmitate (25 μ M) or a combination of these two were used (n=3, independent cell cultures). Error bars indicate s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001. n.s, not significant.




Figure 4. Nuclear PDC regulates the expression of lipid biosynthesis genes independently of mitochondrial PDC.

(a) Western blot analysis of indicated proteins in nuclear and cytoplasmic fractions of shPDHA1 22Rv1 cells infected with NES-PDHA1 and NLS-PDHA1 alone or in combination. Uncropped images are in Supplementary Figure 13. (n=3, independent cell cultures). (b) Western blot analysis of indicated proteins in shPDHA1 22Rv1 cells infected NES-PDHA1 and NLS-PDHA1 alone or in combination (see full panel in Supplementary Fig. 5b). Uncropped images are in Supplementary Figure 13. (n=3, independent cell

cultures). **(c-e)** Quantitative real-time PCR analysis of mRNA expression for *ACLY* **(c)** and *SQLE* **(d)** and determination of citrate levels **(e)** in shRNA control and sh*PDHA1* 22Rv1 and PC3 infected with NES-PDHA1, NLS-PDHA1 alone or in combination (n=3, independent cell cultures). **(f)** Representative confocal images and quantification of lipid droplets (average lipid droplets per cell) in sh*PDHA1* 22Rv1 infected with NES-PDHA1, NLS-PDHA1 alone or in combination (n=3, independent cell cultures, Scale bar represents 10 μ m, 5 fields acquired for each group). **(g)** Upper panel, representative images of crystal violet staining of sh*PDHA1* 22Rv1 infected with infected with NES-PDHA1, NLS-PDHA1 alone or in combination (n=3, independent cell cultures). Lower panel, relative cell number quantification by crystal violet staining in shRNA control and sh*PDHA1* 22Rv1 and PC3 infected with NES-PDHA1, NLS-PDHA1 alone or in combination (n=3, independent cell cultures). **(h)** Upper panel, representative micrographs in histopathological analysis of Ki-67 of these xenograft tumours. Lower panel, evaluation of tumour formation in xenotransplantation experiments of sh*PDHA1* 22Rv1 infected with NES-PDHA1, NLS-PDHA1 alone or in combination (n=6 animals; 12 injections, Scale bar represents 50 μ m, also see Supplementary Fig. 7d for the full panel). Error bars indicate s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001. n.s, not significant.




Figure 5. Nuclear PDC regulates fatty acid synthesis in presence of mitochondrial citrate. (a,b) Relative cell number quantification by crystal violet (a, also see full panel in Supplementary Fig. 8a) and quantification by confocal microscopy of average lipid droplets per cell (b) in shPDHA1 22Rv1 and PC3 cells infected with NES-PDHA1, NLS-PDHA1 alone or in combination and treated with citrate (100 μ M) or vehicle for 6 days (n=3, independent cell cultures). (c) Upper panel, Representative confocal images, and quantification of average lipid droplets per cell, in xenograft tumours from shRNA control and shPDHA1 22Rv1 cells infected with PDK1 or empty vector. Lower panel, Evaluation of

tumour formation in xenotransplantation experiments in shRNA control and sh*PDHA1* 22Rv1 cells infected with PDK1 or empty vector (n=6 animals; 12 injections, 5 fields acquired for each group and Scale Bar represents 20 μ m). **(d)** Upper panel, representative immune-histochemistry micrographs for Ki-67 staining in tumours of the indicated genotypes. (n=6 animals; 12 injections, 5 fields acquired for each group and scale bar represents 50 μ m). Lower panel, quantification of the percentage of Ki-67 positive cells in different tumour genotypes (n=6 animals; 12 injections, 5 fields acquired for each group). **(e,f)** Determination of citrate levels **(e)** and western blot analysis of indicated proteins **(f)** in xenograft tumours from shRNA control and sh*PDHA1* 22Rv1 cells infected with PDK1 or empty vector. Uncropped images are in Supplementary Figure 13. (n=6, independent tumour samples). Error bars indicate s.e.m. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. n.s, not significant.